Overview
Digenic Alport syndrome (Orphanet code 653722) is a rare hereditary kidney disease caused by pathogenic variants in two different genes encoding type IV collagen, typically involving combinations of COL4A3, COL4A4, and/or COL4A5. Unlike the classic forms of Alport syndrome that follow a single-gene inheritance pattern (X-linked, autosomal recessive, or autosomal dominant), digenic Alport syndrome results from the combined effect of heterozygous variants in two of these collagen IV genes, which together produce a more severe phenotype than would be expected from either variant alone. This digenic mechanism helps explain some cases where disease severity does not match predictions based on a single identified variant. The disease primarily affects the kidneys, inner ears, and eyes. The hallmark feature is progressive glomerular disease leading to hematuria (blood in the urine), proteinuria (protein in the urine), and progressive decline in kidney function that can ultimately lead to end-stage kidney disease (ESKD). Sensorineural hearing loss, particularly at high frequencies, is a common associated feature. Ocular abnormalities, including anterior lenticonus and retinal flecks, may also occur. The underlying pathology involves abnormal type IV collagen in the glomerular basement membrane, cochlea, and lens capsule, leading to structural and functional deterioration of these tissues. There is currently no cure for digenic Alport syndrome. Treatment focuses on slowing the progression of kidney disease, primarily through the use of angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs), which reduce proteinuria and delay the onset of end-stage kidney disease. Early initiation of these renoprotective therapies is recommended. Patients who progress to ESKD require renal replacement therapy, including dialysis or kidney transplantation. Hearing aids may be needed for sensorineural hearing loss, and ophthalmologic monitoring is advised for ocular complications. Genetic counseling is important for affected families given the complex inheritance pattern.
Variable
Can be inherited in different ways depending on the underlying gene
Childhood to adulthood
Can begin any time from childhood through adulthood
Treatments
No FDA-approved treatments are currently listed for Digenic Alport syndrome.
View clinical trials →Clinical Trials
View all trials with filters →No actively recruiting trials found for Digenic Alport syndrome at this time.
New trials open frequently. Follow this disease to get notified.
Specialists
View all specialists →No specialists are currently listed for Digenic Alport syndrome.
Treatment Centers
8 centersBaylor College of Medicine Rare Disease Center ↗
Baylor College of Medicine
📍 Houston, TX
🏥 NORDStanford Medicine Rare Disease Center ↗
Stanford Medicine
📍 Stanford, CA
🔬 UDNNIH Clinical Center Undiagnosed Diseases Program ↗
National Institutes of Health
📍 Bethesda, MD
🔬 UDNUCLA UDN Clinical Site ↗
UCLA Health
📍 Los Angeles, CA
🔬 UDNBaylor College of Medicine UDN Clinical Site ↗
Baylor College of Medicine
📍 Houston, TX
🔬 UDNHarvard/MGH UDN Clinical Site ↗
Massachusetts General Hospital
📍 Boston, MA
🏥 NORDMayo Clinic Center for Individualized Medicine ↗
Mayo Clinic
📍 Rochester, MN
👤 Mayo Clinic Center for Individualized Medicine
🏥 NORDUCLA Rare Disease Day Program ↗
UCLA Health
📍 Los Angeles, CA
Travel Grants
No travel grants are currently matched to Digenic Alport syndrome.
Community
No community posts yet. Be the first to share your experience with Digenic Alport syndrome.
Start the conversation →Latest news about Digenic Alport syndrome
No recent news articles for Digenic Alport syndrome.
Follow this condition to be notified when news becomes available.
Caregiver Resources
NORD Caregiver Resources
Support, advocacy, and financial assistance for caregivers of rare disease patients.
Mental Health Support
Rare disease caregiving can be isolating. Connect with counseling and peer support.
Family & Caregiver Grants
Financial assistance programs specifically for caregivers of rare disease patients.
Social Security Disability
Learn how rare disease patients may qualify for SSDI/SSI benefits.
Common questions about Digenic Alport syndrome
What is Digenic Alport syndrome?
Digenic Alport syndrome (Orphanet code 653722) is a rare hereditary kidney disease caused by pathogenic variants in two different genes encoding type IV collagen, typically involving combinations of COL4A3, COL4A4, and/or COL4A5. Unlike the classic forms of Alport syndrome that follow a single-gene inheritance pattern (X-linked, autosomal recessive, or autosomal dominant), digenic Alport syndrome results from the combined effect of heterozygous variants in two of these collagen IV genes, which together produce a more severe phenotype than would be expected from either variant alone. This digen
At what age does Digenic Alport syndrome typically begin?
Typical onset of Digenic Alport syndrome is childhood to adulthood. Age of onset can vary across affected individuals.